Skip to main content

Table 2 Association of MGMT promoter methylation and MGMT and CD133 expression in human GBM

From: MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

  

Total

Methylated

Unmethylated

Not done

MGMT expression

     

Low-expression

+/−, +

42 (55.3%)

20 (26.3%)

22 (29%)

2 (2.6%)

High-expression

++, +++

34 (44.7%)

14 (18.4%)

20 (26.3%)

 

CD133 expression

     

Low-expression

+/−, +

41 (54.7%)

16 (21.3%)

25 (33.4%)

3 (4%)

High-expression

++, +++

34 (45.3%)

18 (24%)

16 (21.3%)

 
  1. Data are represented as the percentage of the total of analyzed patients.